130 related articles for article (PubMed ID: 25553095)
1. Histone H3 phosphorylation in GBM: a new rational to guide the use of kinase inhibitors in anti-GBM therapy.
Pacaud R; Cheray M; Nadaradjane A; Vallette FM; Cartron PF
Theranostics; 2015; 5(1):12-22. PubMed ID: 25553095
[TBL] [Abstract][Full Text] [Related]
2. Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.
Kurokawa C; Geekiyanage H; Allen C; Iankov I; Schroeder M; Carlson B; Bakken K; Sarkaria J; Ecsedy JA; D'Assoro A; Friday B; Galanis E
J Neurooncol; 2017 Jan; 131(1):41-48. PubMed ID: 27816996
[TBL] [Abstract][Full Text] [Related]
3. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
[TBL] [Abstract][Full Text] [Related]
5. Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
DI Cristofori A; Carrabba G; Lanfranchi G; Menghetti C; Rampini P; Caroli M
Anticancer Res; 2013 Aug; 33(8):3383-9. PubMed ID: 23898108
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
7. Post-translational modification and mitochondrial relocalization of histone H3 during apoptosis induced by staurosporine.
Han MJ; Koc EC; Koc H
Biochem Biophys Res Commun; 2014 Jul; 450(1):802-7. PubMed ID: 24952159
[TBL] [Abstract][Full Text] [Related]
8. Regulation of chromatin structure via histone post-translational modification and the link to carcinogenesis.
Thompson LL; Guppy BJ; Sawchuk L; Davie JR; McManus KJ
Cancer Metastasis Rev; 2013 Dec; 32(3-4):363-76. PubMed ID: 23609752
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ
J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
11. Targeting post-translational histone modifying enzymes in glioblastoma.
Kunadis E; Lakiotaki E; Korkolopoulou P; Piperi C
Pharmacol Ther; 2021 Apr; 220():107721. PubMed ID: 33144118
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of serine 10 in histone H3, what for?
Prigent C; Dimitrov S
J Cell Sci; 2003 Sep; 116(Pt 18):3677-85. PubMed ID: 12917355
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of serine-10 of histone H3 shields modified lysine-9 selectively during mitosis.
Jeong YS; Cho S; Park JS; Ko Y; Kang YK
Genes Cells; 2010 Mar; 15(3):181-92. PubMed ID: 20070858
[TBL] [Abstract][Full Text] [Related]
14. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.
Collins GP; Eyre TA; Linton KM; Radford J; Vallance GD; Soilleux E; Hatton C
Br J Haematol; 2015 Sep; 170(6):886-90. PubMed ID: 25721307
[No Abstract] [Full Text] [Related]
16. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
Hirose Y; Berger MS; Pieper RO
Cancer Res; 2001 Aug; 61(15):5843-9. PubMed ID: 11479224
[TBL] [Abstract][Full Text] [Related]
17. Peptidylarginine Deiminases Post-Translationally Deiminate Prohibitin and Modulate Extracellular Vesicle Release and MicroRNAs in Glioblastoma Multiforme.
Kosgodage US; Uysal-Onganer P; MacLatchy A; Kraev I; Chatterton NP; Nicholas AP; Inal JM; Lange S
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30597867
[TBL] [Abstract][Full Text] [Related]
18. Histone phosphorylation: its role during cell cycle and centromere identity in plants.
Zhang B; Dong Q; Su H; Birchler JA; Han F
Cytogenet Genome Res; 2014; 143(1-3):144-9. PubMed ID: 24713809
[TBL] [Abstract][Full Text] [Related]
19. Trivalent dimethylarsenic compound induces histone H3 phosphorylation and abnormal localization of Aurora B kinase in HepG2 cells.
Suzuki T; Miyazaki K; Kita K; Ochi T
Toxicol Appl Pharmacol; 2009 Dec; 241(3):275-82. PubMed ID: 19716834
[TBL] [Abstract][Full Text] [Related]
20. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
